Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C14 covers primary malignant neoplasms arising in otherwise unspecified pharyngeal sites, Waldeyer’s ring, or tumors overlapping contiguous regions of the lip, oral cavity, and pharynx when the site of origin cannot be determined. It is generally used only when a more specific anatomic site cannot be assigned.
Common Histologies
- Squamous cell carcinoma is the predominant epithelial malignancy.
- Less common tumors include salivary-type carcinomas and undifferentiated carcinomas.
- Lymphomas may involve Waldeyer’s ring but are classified in the lymphoma families rather than by C14 site codes.
Common Symptoms
Presentation varies by extent and may include:
- Persistent sore throat (R07.0), dysphagia (R13.10), or odynophagia (R07.0)
- Referred otalgia (H92.09)
- Mucosal ulceration (K12.30), mass (K13.70), or bleeding (R58)
- Voice change (R49.0), trismus (R68.84), or airway symptoms (R49.0)
- Unexplained weight loss (R63.4)
- Cervical lymphadenopathy, sometimes as the initial finding (R59.0)
Diagnosis
Evaluation typically includes complete head and neck examination, flexible endoscopy, and tissue biopsy. Contrast-enhanced CT or MRI assesses local extent and cervical nodes; FDG-PET/CT may be used for advanced disease, occult primary evaluation, or distant staging. When the primary site is uncertain, examination under anesthesia with directed biopsies may help identify its origin.
Staging
Staging depends on the actual anatomic site, histology, tumor extent, nodal disease, and distant metastases. HPV-mediated oropharyngeal squamous cell carcinoma has a distinct staging framework, so determining whether a tumor arises from an HPV-associated oropharyngeal structure is important. An ill-defined or overlapping site may limit application of site-specific staging rules.
Molecular Markers
- High-risk HPV testing, commonly using p16 immunohistochemistry as a surrogate in appropriate oropharyngeal squamous cell carcinomas
- EBV testing when morphology and clinical location suggest an EBV-associated nasopharyngeal-type carcinoma
- PD-L1 assessment in recurrent or metastatic squamous cell carcinoma when systemic immunotherapy is being considered
- Broader molecular profiling in selected recurrent, metastatic, salivary-type, or otherwise unusual tumors
Common Treatments
Management is multidisciplinary and depends on the suspected site of origin, resectability, stage, histology, and functional impact. Options include surgery with appropriate neck management, definitive radiation therapy, concurrent chemoradiation, or combined-modality treatment. Recurrent or metastatic disease may be treated with immunotherapy, platinum-based regimens, other systemic therapy, reirradiation, surgery, or symptom-directed care. Nutritional, dental, speech, swallowing, and airway support are often integral to treatment.
Scope Note
C14 encodes the primary anatomic site of a malignant neoplasm in specified other, overlapping, or ill-defined regions of the lip, oral cavity, and pharynx. C14.8 applies when a single tumor overlaps contiguous sites and its point of origin cannot be determined; it should not replace a known, more specific site. Oral cavity malignancy not otherwise specified is excluded from this family and is classified under C06.9. The code does not encode histology, HPV or EBV status, TNM stage, grade, nodal involvement, or treatment status. Secondary or metastatic involvement is not coded as a primary C14 malignancy. When applicable, the classification also directs additional coding to identify alcohol abuse or dependence and exposure to environmental tobacco smoke.